Every lot published · search any lot number before you order

Retatrutide Phase 2 Results at 24 Weeks

At 24 weeks, the Phase 2 paper reported an estimated mean change of −17.5% in the 12 mg group and −1.6% in the placebo group. This time point was specified for the primary weight endpoint.

Retatrutide Phase 2 Results at 24 Weeks. The Phase 2 primary time point. 12 mg arm, 24 weeks, 17.5% mean loss. GLP LIFE SCIENCES · RESEARCH BRIEF 12 The Phase 2 primary time point Weight loss studies 12 mg arm24 weeks17.5% mean loss
The Phase 2 primary time point. Illustration for this research brief.

The Phase 2 primary time point

The later 48-week results came from continued follow-up in the same study. Comparing two time points helps explain the trajectory observed in that trial, while leaving open what happens over longer periods.

How to interpret the evidence

For an accurate summary, identify the assigned study arm and keep the 24-week and 48-week figures labeled separately.

When comparing results, record the primary outcome, the measurement week, and whether the analysis included outcomes after treatment stopped.

Sources